LVCLY Living Cell Technologies Ltd featured news, full reports, and detailed charts
Living Cell Technologies Ltd (LVCLY/LVCLY.PK) Wrap Up:
Living Cell Technologies Limited, a biotechnology company, engages in the clinical development of cell based therapeutics for the treatment of diabetes, as well as preclinical research and development into neurological disorders in New Zealand and the United States. It owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at reduced levels; and for the treatment of Huntington’s disease and other neurological disorders, Living Cell Technologi...Living Cell Technologies Ltd (LVCLY:Pink OTC Markets Inc - International Prime QX)
|
Market Cap
70.3M
|
Total Revenue
789.9K
|
|
|
EBITDA
6.9M
|
DILUTED EPS TTM
-0.03
|
|
|
P/E
--
|
P/S
101.3x
|
|
|
Return On Asset
-48.05
|
Return On Equity
-71.81
|
|
| K = Thousands M = Millions B = Billions | ||
LVCLY Top Compensated Officers
Executives, Board Directors
Key developments for Living Cell Technologies Ltd (LVCLY)
Living Cell Technologies Ltd., Annual General Meeting, Nov 19, 2009, at 12:00 EAST-East Australian Standard GST. Location: Kemp Strang, Level 14, 55 Hunter Street, Sydney, NSW 2000, Australia. Agenda: To consider the financial report and the reports of the directors and auditors for the year ended 30 June 2009; to approve the remuneration report; to approve the election and re-election of directors; to approve the issue of options to Robert Finder or his nominee in accordance with Listing Rule 10.11; to approve the issue of options to David McAuliffe or his nominee in accordance with Listing Rule 10.11; to approve the issue of options to David Brookes or his nominee in accordance with Listing Rule 10.11; to approve the directors deed of access, insurance and indemnity.
Living Cell Technologies Ltd. announced the appointment of Bob Finder and David McAuliffe as independent directors and the election of David Brookes as chairman. Mr. Finder has 35 years' experience in the international biotech/pharmaceutical and chemical industries. He is chairman of LabTech System and a director of National Pharmacies. Mr. McAuliffe has 14 years' experience in the international Life Science sector. During this time he has been involved in numerous capital raisings and technology in-licensing exercises. He is the founder of NeuroDiscovery and has been a director since establishment. Simon O'Loughlin has decided to stand down as chairman due to other commitments. The new chairman, Dr. Brookes, has been an independent director since August 2007.
Living Cell Technologies Ltd. announced preliminary earnings results for the full year ended June 30, 2009. For the period, the company reported pre tax loss and loss after tax was AUD 6,123,600 or AUD 0.0257 per share compared to AUD 6,794,000 or AUD 0.0354 per share for the same period last year. Negative operating cash flow was AUD 5,703,600 compared to AUD 5,598,200 for the same period last year. Negative return on equity was 110.8% compared to 58.9% for the same period last year. Negative return on assets was 94.2% compared to 55.5% for the same period last year.
LVCLY Competitors
| Company | Last | Change |
| Geron Corp | $5.58 USD | -0.15 |
| Tissera Inc | $0.01 USD | 0.00 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | LVCLY | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 101.3x |
|
| Price/Book | 14.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 108.7x |
|
|
LVCLY |
||
LVCLY transactions
| Type Date |
Target |
|
Private Placement
July 30, 2009 |
-- |